New drug combination could give prostate cancer patients months of extra life trends now
New drug combination could give prostate cancer patients months of extra life trends now
New drug combination could give prostate cancer patients months of extra life and revolutionise treatment Scientists have added olaparib to the testosterone blocker abiratone The combination was found to extend the life of stage 4 patients by 7.4 months
View
comments
A new drug combination could give prostate cancer patients months of extra life and revolutionise treatment.
The usual procedure when the disease has spread is to fight tumours with drugs that block testosterone.
In aggressive cases, however, this hormone therapy can cease to be effective.
According to The Mirror, scientists have added olaparib - a DNA repair enzyme blocker in cancer cells - to the testosterone stopper abiratone.
After a trial involving 800
